NCT07170995View on ClinicalTrials.gov

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
DRUG

SHR-8068，adebelizumab and platinum-based chemotherapy

SHR-8068，adebelizumab and platinum-based chemotherapy

DRUG

tislelizumab, and platinum-based chemotherapy

tislelizumab, and platinum-based chemotherapy

Trial Locations (1)

250117

Affiliated Cancer Hospital of Shandong First Medical University, Jinan

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY